The Phase II trial for an Israeli COVID drug saw some 29 out of 30 patients, moderate to serious, recover within days. Read print story.
By Rossella Tercatin | posted 8/5/2021
The Phase II trial for an Israeli COVID drug saw some 29 out of 30 patients, moderate to serious, recover within days. Read print story.
By Rossella Tercatin | posted 8/5/2021
